CN116478245A - 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物 - Google Patents

通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物 Download PDF

Info

Publication number
CN116478245A
CN116478245A CN202310436312.6A CN202310436312A CN116478245A CN 116478245 A CN116478245 A CN 116478245A CN 202310436312 A CN202310436312 A CN 202310436312A CN 116478245 A CN116478245 A CN 116478245A
Authority
CN
China
Prior art keywords
compound
peptide
cancer
peptide compound
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310436312.6A
Other languages
English (en)
Chinese (zh)
Inventor
理查德·贝利沃
博尔汉·阿纳比
米歇尔·德米勒
阿兰·拉洛克
吉恩-克里斯托夫·柯里
辛迪亚·沙菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus SC
Original Assignee
Transfert Plus SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus SC filed Critical Transfert Plus SC
Publication of CN116478245A publication Critical patent/CN116478245A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202310436312.6A 2015-11-24 2016-11-24 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物 Pending CN116478245A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562259178P 2015-11-24 2015-11-24
US62/259,178 2015-11-24
CN201680078822.9A CN108473541B (zh) 2015-11-24 2016-11-24 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物
PCT/CA2016/051379 WO2017088058A1 (en) 2015-11-24 2016-11-24 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680078822.9A Division CN108473541B (zh) 2015-11-24 2016-11-24 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物

Publications (1)

Publication Number Publication Date
CN116478245A true CN116478245A (zh) 2023-07-25

Family

ID=58762819

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310436312.6A Pending CN116478245A (zh) 2015-11-24 2016-11-24 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物
CN201680078822.9A Active CN108473541B (zh) 2015-11-24 2016-11-24 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680078822.9A Active CN108473541B (zh) 2015-11-24 2016-11-24 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物

Country Status (13)

Country Link
US (4) US11034727B2 (enExample)
EP (2) EP3380495B1 (enExample)
JP (2) JP6810146B2 (enExample)
CN (2) CN116478245A (enExample)
AU (2) AU2016358324B2 (enExample)
CA (2) CA3071494C (enExample)
DK (1) DK3380495T3 (enExample)
ES (2) ES2882634T3 (enExample)
PL (1) PL3380495T3 (enExample)
PT (1) PT3380495T (enExample)
SI (1) SI3380495T1 (enExample)
WO (1) WO2017088058A1 (enExample)
ZA (1) ZA201804117B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118384289A (zh) * 2024-04-24 2024-07-26 青岛科技大学 一种肿瘤靶向肽及多肽偶联药物的制备方法及应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3380495T (pt) 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
CN110945016A (zh) * 2017-05-24 2020-03-31 特拉斯福特普拉斯公司 用于治疗炎性疾病的肽化合物、缀合化合物及其用途
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
WO2020037434A1 (en) * 2018-08-24 2020-02-27 Transfert Plus, S.E.C. Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
EP3986921A2 (en) * 2019-06-20 2022-04-27 Aarhus Universitet Sorcs2 crystal structure and uses thereof
AU2020395148A1 (en) * 2019-12-06 2022-06-23 Theratechnologies Inc. Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer
US20230338555A1 (en) * 2020-05-18 2023-10-26 Ionis Pharmaceuticals, Inc. Conjugated oligonucleotides and uses thereof
CA3208147A1 (en) * 2021-02-26 2022-09-01 Richard Beliveau Methods and compounds for targeting cancer stem cells
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
WO2024103161A1 (en) * 2022-11-14 2024-05-23 Theratechnologies Inc. Drug conjugate compounds for stimulating the antitumor immune response
CN122249236A (zh) * 2023-09-11 2026-06-19 瑟瑞技术公司 喜树碱类似物的肽缀合物及其用途
CN117904303B (zh) * 2024-03-18 2024-06-18 湖南宏雅基因技术有限公司 Sorcs1基因甲基化和pax1基因甲基化联合诊断的检测引物探针组在制备宫颈癌诊断产品中的应用
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof
TW202604936A (zh) * 2024-07-25 2026-02-01 大陸商上海湃鴻生物科技有限公司 一種多肽藥物偶聯物及其製備方法和應用
WO2026080471A2 (en) 2024-10-07 2026-04-16 Flagship Pioneering Innovations Vi, Llc Compositions of trem conjugates and uses thereof
US20260109780A1 (en) * 2024-10-21 2026-04-23 Sonnet BioTherapeutics, Inc. Docking peptides and related antibody-based drug conjugates

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700930A1 (en) * 1994-06-07 1996-03-13 NIHON MEDI-PHYSICS Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide
CN102159248A (zh) * 2008-07-15 2011-08-17 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
CN103298481A (zh) * 2010-11-17 2013-09-11 翁科里克斯公司 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途
US20150202316A1 (en) * 2014-01-17 2015-07-23 Academia Sinica Lung cancer specific peptides for targeted drug delivery and molecular imaging
CN104884056A (zh) * 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
FI101678B (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US8344211B2 (en) 2008-08-13 2013-01-01 Ceres, Inc. Plant nucleotide sequences and corresponding polypeptides
TW200634019A (en) 2004-12-21 2006-10-01 Wyeth Corp Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors
JP5123936B2 (ja) * 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 認知症の検出および治療
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
WO2009132656A2 (en) * 2008-04-27 2009-11-05 H. Lundbeck A/S Design of specific ligands to sortilin
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
CA2786255A1 (en) 2009-12-31 2011-07-07 Organomed Corporation Formulations from natural products, turmeric, and aspirin
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
EP3991748A3 (en) * 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
PT3380495T (pt) * 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
CN110945016A (zh) * 2017-05-24 2020-03-31 特拉斯福特普拉斯公司 用于治疗炎性疾病的肽化合物、缀合化合物及其用途
WO2020037434A1 (en) * 2018-08-24 2020-02-27 Transfert Plus, S.E.C. Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700930A1 (en) * 1994-06-07 1996-03-13 NIHON MEDI-PHYSICS Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide
CN102159248A (zh) * 2008-07-15 2011-08-17 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
CN103298481A (zh) * 2010-11-17 2013-09-11 翁科里克斯公司 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途
CN104884056A (zh) * 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
US20150202316A1 (en) * 2014-01-17 2015-07-23 Academia Sinica Lung cancer specific peptides for targeted drug delivery and molecular imaging

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118384289A (zh) * 2024-04-24 2024-07-26 青岛科技大学 一种肿瘤靶向肽及多肽偶联药物的制备方法及应用

Also Published As

Publication number Publication date
US11034727B2 (en) 2021-06-15
EP3925969C0 (en) 2025-09-03
EP3380495A4 (en) 2019-02-27
CN108473541B (zh) 2023-05-12
CN108473541A (zh) 2018-08-31
US20240199695A1 (en) 2024-06-20
JP2020189867A (ja) 2020-11-26
PL3380495T3 (pl) 2021-12-13
CA3071494A1 (en) 2017-06-01
JP2019501141A (ja) 2019-01-17
ZA201804117B (en) 2022-08-31
WO2017088058A1 (en) 2017-06-01
AU2021201085B2 (en) 2023-01-19
AU2021201085A1 (en) 2021-03-11
JP6810146B2 (ja) 2021-01-06
US20250296957A1 (en) 2025-09-25
ES2882634T3 (es) 2021-12-02
CA3006313A1 (en) 2017-06-01
AU2016358324B2 (en) 2021-03-11
US20200392184A1 (en) 2020-12-17
EP3925969B1 (en) 2025-09-03
SI3380495T1 (sl) 2022-01-31
PT3380495T (pt) 2021-08-19
US12269902B2 (en) 2025-04-08
CA3071494C (en) 2021-12-14
ES3053967T3 (en) 2026-01-28
US11780882B2 (en) 2023-10-10
EP3380495A1 (en) 2018-10-03
DK3380495T3 (da) 2021-08-16
US20220356209A1 (en) 2022-11-10
AU2016358324A1 (en) 2018-07-05
EP3925969A1 (en) 2021-12-22
BR112018010535A2 (pt) 2018-11-13
EP3380495B1 (en) 2021-05-19
JP7095035B2 (ja) 2022-07-04
CA3006313C (en) 2020-02-11

Similar Documents

Publication Publication Date Title
JP7095035B2 (ja) 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート
CN113286820B (zh) 用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物
JP2018502047A (ja) 生物学的物質及びその使用
JP7780253B2 (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
AU2015252518A2 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
CN114980932B (zh) Sortilin结合缀合化合物、其组合物及其用于治疗癌症的用途
JP2020527596A (ja) 炎症性疾患の治療のためのペプチド化合物、コンジュゲート化合物及びそれらの使用
WO2016108587A1 (ko) 리피바디 유도체-약물 복합체, 그 제조방법 및 용도
JP5677453B2 (ja) Ｂｐｂベースのカーゴ運搬システム
HK1259948B (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
HK40066016B (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
HK40066016A (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
HK1259948A1 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
BR112018010535B1 (pt) Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
CZ200132A3 (cs) Podávači systém

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination